JAK2 and lung carcinoma: Culturing A549 or CL1-5 lung cancer cells with bone marrow mesenchymal stem cells (MSCs) can increase spheroid formation, drug resistance and overexpression of pluripotent markers by activating IL-6/JAK2/STAT3 pathway (22).